Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
JANX
JANX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
JANX News
Janux Therapeutics Reports Increased Q4 Losses
Feb 27 2026
NASDAQ.COM
Janux Therapeutics Q4 Earnings Beat Expectations
Feb 26 2026
seekingalpha
Janux Therapeutics and Bristol Myers Squibb Sign $800 Million Collaboration Agreement
Jan 22 2026
Benzinga
Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for Tumor-Activated Therapy Development
Jan 22 2026
stocktwits
Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for $50M Collaboration on Solid Tumor Therapy
Jan 22 2026
NASDAQ.COM
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million
Jan 22 2026
seekingalpha
Janux Completes Phase 1a Trial for JANX008, Initiates Expansion Cohorts
Dec 24 2025
NASDAQ.COM
Janux Initiates Expansion Phase for JANX008 Clinical Trial Targeting EGFR
Dec 23 2025
Businesswire
Janux Executive Sells 16,665 Shares for $501,000 Through Options Exercise
Dec 04 2025
NASDAQ.COM
Stifel Continues to Recommend Buy for Janux Therapeutics (JANX)
Dec 03 2025
NASDAQ.COM
Gold Declines More Than 1%; Signet Stock Drops Following Q3 Earnings Report
Dec 02 2025
Benzinga
Midday Stock Highlights: Maplebear, Boeing, Credo Technology, XPO, MongoDB, and Others
Dec 02 2025
CNBC
Janux Therapeutics Shares Reach 52-Week Low Following Trial Announcement
Dec 02 2025
Benzinga
Nasdaq Rises by 200 Points as United Natural Foods Reports Positive Earnings
Dec 02 2025
Benzinga
Applied Materials Expected to Surge by 12%? Check Out 10 Leading Analyst Predictions for Tuesday
Dec 02 2025
Benzinga
Signet Jewelers, Janux Therapeutics, BW LPG, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
Dec 02 2025
Benzinga
Show More News
